Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for reducing mortality and morbidity after Permcath catheterization
IRCT20201028049175N10Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atorvastatin in catheter-related complication and end-stage kidney disease (ESKD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Mortality rate, Cardiac arrhythmia and 4 more. Started Nov 2021; status: completed.
02
Drugs
atorvastatin
03
Conditions
catheter-related complicationend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20201028049175N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201028049175N10.